 Kennon Heard
Concepts (647)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acetaminophen | 40 | 2025 | 266 | 8.500 |
Why?
| | Chemical and Drug Induced Liver Injury | 15 | 2023 | 136 | 4.750 |
Why?
| | Analgesics, Non-Narcotic | 21 | 2025 | 124 | 4.580 |
Why?
| | Drug Overdose | 31 | 2025 | 345 | 4.200 |
Why?
| | Poison Control Centers | 13 | 2025 | 90 | 3.470 |
Why?
| | Emergency Service, Hospital | 41 | 2023 | 2046 | 3.380 |
Why?
| | Poisoning | 17 | 2017 | 116 | 3.010 |
Why?
| | Alanine Transaminase | 14 | 2023 | 157 | 2.590 |
Why?
| | Acetylcysteine | 11 | 2023 | 145 | 2.590 |
Why?
| | Cocaine | 10 | 2011 | 166 | 2.420 |
Why?
| | Cannabis | 9 | 2020 | 487 | 2.340 |
Why?
| | Prescription Drugs | 9 | 2018 | 109 | 2.240 |
Why?
| | Analgesics, Opioid | 8 | 2023 | 992 | 1.540 |
Why?
| | Antidotes | 9 | 2020 | 143 | 1.500 |
Why?
| | Legislation, Drug | 5 | 2017 | 80 | 1.480 |
Why?
| | Cysteine | 4 | 2017 | 204 | 1.360 |
Why?
| | Antipsychotic Agents | 7 | 2019 | 193 | 1.330 |
Why?
| | Marijuana Use | 4 | 2021 | 203 | 1.210 |
Why?
| | Medication Errors | 5 | 2015 | 95 | 1.160 |
Why?
| | Male | 103 | 2022 | 67309 | 1.120 |
Why?
| | Emergency Medicine | 6 | 2019 | 226 | 1.100 |
Why?
| | Cocaine-Related Disorders | 5 | 2011 | 113 | 1.100 |
Why?
| | Pain | 9 | 2020 | 754 | 1.100 |
Why?
| | Humans | 155 | 2025 | 136764 | 1.090 |
Why?
| | Drug Packaging | 2 | 2017 | 45 | 1.060 |
Why?
| | Toxicology | 4 | 2021 | 46 | 1.050 |
Why?
| | Female | 95 | 2022 | 72787 | 0.970 |
Why?
| | Medication Reconciliation | 2 | 2016 | 29 | 0.960 |
Why?
| | Adult | 73 | 2022 | 37630 | 0.960 |
Why?
| | Dose-Response Relationship, Drug | 16 | 2017 | 2052 | 0.940 |
Why?
| | Antidepressive Agents, Tricyclic | 5 | 2014 | 30 | 0.890 |
Why?
| | Spider Bites | 5 | 2019 | 9 | 0.890 |
Why?
| | Antivenins | 5 | 2019 | 36 | 0.880 |
Why?
| | Diphenhydramine | 4 | 2023 | 37 | 0.870 |
Why?
| | Akathisia, Drug-Induced | 2 | 2020 | 6 | 0.860 |
Why?
| | Thiazoles | 4 | 2009 | 123 | 0.850 |
Why?
| | Prescription Drug Monitoring Programs | 1 | 2023 | 14 | 0.830 |
Why?
| | Spider Venoms | 4 | 2019 | 11 | 0.820 |
Why?
| | Benzodiazepines | 6 | 2023 | 153 | 0.820 |
Why?
| | Heart Arrest | 8 | 2018 | 338 | 0.800 |
Why?
| | Muscarinic Antagonists | 3 | 2023 | 29 | 0.790 |
Why?
| | Lorazepam | 3 | 2023 | 27 | 0.790 |
Why?
| | Young Adult | 30 | 2020 | 13129 | 0.770 |
Why?
| | Middle Aged | 54 | 2022 | 33228 | 0.770 |
Why?
| | Seizures | 6 | 2011 | 425 | 0.750 |
Why?
| | Decision Support Systems, Clinical | 2 | 2023 | 223 | 0.750 |
Why?
| | Referral and Consultation | 2 | 2020 | 780 | 0.740 |
Why?
| | Physostigmine | 2 | 2020 | 12 | 0.740 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 350 | 0.730 |
Why?
| | Emergency Treatment | 4 | 2015 | 118 | 0.730 |
Why?
| | Piperazines | 4 | 2009 | 350 | 0.730 |
Why?
| | Black Widow Spider | 4 | 2019 | 9 | 0.730 |
Why?
| | Medical History Taking | 3 | 2018 | 117 | 0.720 |
Why?
| | Dopamine Uptake Inhibitors | 3 | 2011 | 59 | 0.720 |
Why?
| | Delirium | 2 | 2020 | 89 | 0.710 |
Why?
| | Anti-Arrhythmia Agents | 4 | 2014 | 114 | 0.680 |
Why?
| | Abdominal Pain | 2 | 2019 | 145 | 0.670 |
Why?
| | Suicide, Attempted | 5 | 2012 | 373 | 0.670 |
Why?
| | Hospitals, Pediatric | 4 | 2018 | 506 | 0.660 |
Why?
| | Back Pain | 1 | 2020 | 50 | 0.650 |
Why?
| | Vasoconstrictor Agents | 4 | 2009 | 139 | 0.650 |
Why?
| | Emergency Medical Services | 5 | 2025 | 547 | 0.640 |
Why?
| | Free Radical Scavengers | 2 | 2011 | 88 | 0.640 |
Why?
| | Patient Handoff | 1 | 2020 | 32 | 0.640 |
Why?
| | Retrospective Studies | 31 | 2023 | 15504 | 0.640 |
Why?
| | Buprenorphine | 2 | 2020 | 169 | 0.630 |
Why?
| | Ketorolac | 1 | 2019 | 20 | 0.620 |
Why?
| | Haloperidol | 1 | 2019 | 34 | 0.620 |
Why?
| | Social Work | 1 | 2020 | 85 | 0.600 |
Why?
| | Pharmacoepidemiology | 1 | 2018 | 19 | 0.600 |
Why?
| | Gastric Lavage | 3 | 2009 | 9 | 0.580 |
Why?
| | Tertiary Care Centers | 3 | 2017 | 159 | 0.580 |
Why?
| | Immunoglobulin Fab Fragments | 4 | 2019 | 59 | 0.580 |
Why?
| | Colorado | 15 | 2021 | 4518 | 0.570 |
Why?
| | Vomiting | 6 | 2019 | 130 | 0.570 |
Why?
| | Prospective Studies | 18 | 2023 | 7572 | 0.560 |
Why?
| | Substance-Related Disorders | 5 | 2012 | 1069 | 0.560 |
Why?
| | Hypotension | 2 | 2022 | 122 | 0.560 |
Why?
| | Drug Storage | 2 | 2017 | 57 | 0.550 |
Why?
| | Child | 28 | 2023 | 21822 | 0.540 |
Why?
| | Accidents, Home | 1 | 2017 | 31 | 0.540 |
Why?
| | Electronic Health Records | 4 | 2024 | 1046 | 0.540 |
Why?
| | Cannabinoids | 3 | 2017 | 161 | 0.530 |
Why?
| | Medical Marijuana | 2 | 2019 | 117 | 0.530 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2007 | 82 | 0.530 |
Why?
| | Plant Preparations | 2 | 2015 | 36 | 0.530 |
Why?
| | Pulmonary Embolism | 3 | 2021 | 225 | 0.520 |
Why?
| | Calcium Gluconate | 1 | 2016 | 4 | 0.520 |
Why?
| | Hypocalcemia | 1 | 2016 | 27 | 0.510 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2016 | 52 | 0.510 |
Why?
| | Health Records, Personal | 1 | 2016 | 27 | 0.500 |
Why?
| | Nonprescription Drugs | 4 | 2016 | 63 | 0.490 |
Why?
| | Blood Proteins | 1 | 2017 | 252 | 0.490 |
Why?
| | Mobile Applications | 1 | 2018 | 182 | 0.480 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 5 | 2023 | 250 | 0.480 |
Why?
| | Practice Patterns, Physicians' | 3 | 2023 | 1301 | 0.480 |
Why?
| | Fat Emulsions, Intravenous | 2 | 2014 | 30 | 0.480 |
Why?
| | Antidepressive Agents | 2 | 2012 | 235 | 0.480 |
Why?
| | Prescription Drug Misuse | 1 | 2015 | 40 | 0.470 |
Why?
| | Liver | 6 | 2022 | 1940 | 0.460 |
Why?
| | Treatment Outcome | 18 | 2020 | 10744 | 0.460 |
Why?
| | Electrocardiography | 5 | 2013 | 629 | 0.460 |
Why?
| | Child, Preschool | 13 | 2018 | 11000 | 0.440 |
Why?
| | Infant | 12 | 2018 | 9398 | 0.440 |
Why?
| | Asymptomatic Diseases | 2 | 2013 | 89 | 0.430 |
Why?
| | Crime | 2 | 2011 | 60 | 0.430 |
Why?
| | Observer Variation | 3 | 2010 | 341 | 0.430 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 24 | 0.420 |
Why?
| | Energy Drinks | 1 | 2013 | 4 | 0.420 |
Why?
| | Performance-Enhancing Substances | 1 | 2013 | 10 | 0.410 |
Why?
| | Accidents | 1 | 2013 | 37 | 0.410 |
Why?
| | Arrhythmias, Cardiac | 3 | 2022 | 333 | 0.410 |
Why?
| | Adolescent | 27 | 2020 | 21382 | 0.410 |
Why?
| | Bradycardia | 1 | 2013 | 55 | 0.410 |
Why?
| | Plasmapheresis | 1 | 2013 | 24 | 0.410 |
Why?
| | Double-Blind Method | 7 | 2020 | 1981 | 0.400 |
Why?
| | Diet Surveys | 1 | 2013 | 95 | 0.400 |
Why?
| | Amphotericin B | 1 | 2013 | 31 | 0.400 |
Why?
| | Poisons | 2 | 2023 | 23 | 0.400 |
Why?
| | Hematemesis | 1 | 2012 | 3 | 0.400 |
Why?
| | beta-Alanine | 1 | 2012 | 16 | 0.400 |
Why?
| | Stomach Diseases | 1 | 2012 | 20 | 0.400 |
Why?
| | Aspartate Aminotransferases | 3 | 2010 | 90 | 0.400 |
Why?
| | Phytotherapy | 1 | 2013 | 83 | 0.400 |
Why?
| | Foreign Bodies | 2 | 2011 | 104 | 0.400 |
Why?
| | Ethers | 1 | 2012 | 19 | 0.400 |
Why?
| | Sulfonylurea Compounds | 2 | 2010 | 48 | 0.390 |
Why?
| | Citalopram | 1 | 2012 | 29 | 0.390 |
Why?
| | Antithrombins | 1 | 2012 | 60 | 0.380 |
Why?
| | Liver Function Tests | 7 | 2020 | 114 | 0.380 |
Why?
| | Antifungal Agents | 1 | 2013 | 136 | 0.380 |
Why?
| | Drug Administration Schedule | 5 | 2014 | 785 | 0.380 |
Why?
| | Propafenone | 1 | 2011 | 2 | 0.380 |
Why?
| | Thiophenes | 1 | 2012 | 117 | 0.370 |
Why?
| | Aged | 27 | 2019 | 23794 | 0.370 |
Why?
| | C-Peptide | 2 | 2010 | 163 | 0.370 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 2412 | 0.370 |
Why?
| | Dronabinol | 4 | 2021 | 226 | 0.370 |
Why?
| | Firesetting Behavior | 1 | 2011 | 1 | 0.370 |
Why?
| | Disease Models, Animal | 9 | 2011 | 4281 | 0.370 |
Why?
| | Opioid-Related Disorders | 2 | 2020 | 509 | 0.360 |
Why?
| | Infusions, Intravenous | 6 | 2013 | 412 | 0.360 |
Why?
| | Clinical Enzyme Tests | 2 | 2013 | 11 | 0.360 |
Why?
| | Anaphylaxis | 2 | 2012 | 105 | 0.360 |
Why?
| | Charcoal | 4 | 2006 | 25 | 0.360 |
Why?
| | Alcohol Drinking | 4 | 2012 | 820 | 0.360 |
Why?
| | Benzimidazoles | 1 | 2012 | 170 | 0.360 |
Why?
| | Temperance | 2 | 2010 | 13 | 0.360 |
Why?
| | Administration, Intravenous | 4 | 2016 | 155 | 0.350 |
Why?
| | Chemical and Drug Induced Liver Injury, Chronic | 1 | 2011 | 12 | 0.350 |
Why?
| | Brain Edema | 1 | 2011 | 61 | 0.350 |
Why?
| | Cholinergic Antagonists | 1 | 2011 | 30 | 0.350 |
Why?
| | Amitriptyline | 2 | 2001 | 21 | 0.350 |
Why?
| | Blood Chemical Analysis | 3 | 2021 | 99 | 0.340 |
Why?
| | Aged, 80 and over | 15 | 2018 | 7585 | 0.340 |
Why?
| | Evidence-Based Medicine | 4 | 2023 | 738 | 0.340 |
Why?
| | Self-Injurious Behavior | 1 | 2012 | 129 | 0.340 |
Why?
| | Burns | 2 | 2015 | 325 | 0.340 |
Why?
| | Reproducibility of Results | 6 | 2024 | 3264 | 0.340 |
Why?
| | Immunologic Factors | 2 | 2019 | 236 | 0.340 |
Why?
| | Tachycardia, Ventricular | 1 | 2012 | 175 | 0.340 |
Why?
| | Liver Failure | 1 | 2011 | 94 | 0.330 |
Why?
| | Hydrofluoric Acid | 2 | 2016 | 8 | 0.330 |
Why?
| | Pharmaceutical Vehicles | 1 | 2010 | 12 | 0.330 |
Why?
| | Propylene Glycol | 1 | 2010 | 10 | 0.330 |
Why?
| | Time Factors | 12 | 2020 | 6806 | 0.330 |
Why?
| | Barium | 1 | 2009 | 26 | 0.330 |
Why?
| | Population Surveillance | 1 | 2013 | 474 | 0.330 |
Why?
| | Explosive Agents | 1 | 2009 | 6 | 0.330 |
Why?
| | United States | 18 | 2025 | 14691 | 0.330 |
Why?
| | Hypokalemia | 1 | 2009 | 24 | 0.320 |
Why?
| | Imines | 2 | 2022 | 8 | 0.320 |
Why?
| | Liver Diseases, Alcoholic | 2 | 2007 | 93 | 0.320 |
Why?
| | Acidosis, Lactic | 1 | 2010 | 46 | 0.320 |
Why?
| | Warfarin | 1 | 2010 | 153 | 0.320 |
Why?
| | Iatrogenic Disease | 1 | 2010 | 66 | 0.320 |
Why?
| | Emetics | 2 | 2006 | 7 | 0.320 |
Why?
| | Deception | 1 | 2009 | 20 | 0.310 |
Why?
| | Random Allocation | 3 | 2007 | 353 | 0.310 |
Why?
| | Cross-Sectional Studies | 9 | 2020 | 5423 | 0.310 |
Why?
| | Benzoquinones | 2 | 2022 | 48 | 0.310 |
Why?
| | Surveys and Questionnaires | 4 | 2018 | 5742 | 0.310 |
Why?
| | Risk Factors | 9 | 2017 | 10326 | 0.300 |
Why?
| | Oximetry | 1 | 2009 | 96 | 0.300 |
Why?
| | Risk Assessment | 8 | 2017 | 3432 | 0.300 |
Why?
| | Fluorides | 2 | 2016 | 49 | 0.300 |
Why?
| | Odds Ratio | 7 | 2017 | 1065 | 0.300 |
Why?
| | Hypothermia, Induced | 1 | 2009 | 79 | 0.300 |
Why?
| | Length of Stay | 3 | 2020 | 1205 | 0.300 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 163 | 0.290 |
Why?
| | Cyanoacrylates | 1 | 2008 | 4 | 0.290 |
Why?
| | Eyelashes | 1 | 2008 | 4 | 0.290 |
Why?
| | Adhesives | 1 | 2008 | 14 | 0.280 |
Why?
| | Hypoglycemia | 2 | 2010 | 442 | 0.280 |
Why?
| | Detergents | 1 | 2008 | 44 | 0.280 |
Why?
| | Intellectual Disability | 1 | 2009 | 164 | 0.280 |
Why?
| | Reference Values | 4 | 2017 | 816 | 0.280 |
Why?
| | Alcoholism | 4 | 2023 | 804 | 0.280 |
Why?
| | Animals | 22 | 2019 | 36823 | 0.280 |
Why?
| | Cardiovascular System | 1 | 2009 | 137 | 0.280 |
Why?
| | Publishing | 1 | 2009 | 145 | 0.270 |
Why?
| | Brugada Syndrome | 1 | 2007 | 10 | 0.270 |
Why?
| | Niacin | 1 | 2007 | 17 | 0.270 |
Why?
| | Diazepam | 1 | 2007 | 35 | 0.270 |
Why?
| | Clinical Laboratory Techniques | 1 | 2008 | 97 | 0.270 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 640 | 0.270 |
Why?
| | Mice, Inbred Strains | 4 | 2009 | 409 | 0.270 |
Why?
| | Vitamin B Complex | 1 | 2007 | 43 | 0.260 |
Why?
| | Pediatrics | 1 | 2015 | 1096 | 0.260 |
Why?
| | Thromboembolism | 1 | 2007 | 119 | 0.260 |
Why?
| | Brain Infarction | 1 | 2006 | 23 | 0.260 |
Why?
| | Specimen Handling | 1 | 2008 | 181 | 0.260 |
Why?
| | Analgesics | 4 | 2017 | 205 | 0.250 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2006 | 37 | 0.250 |
Why?
| | Nausea | 4 | 2014 | 111 | 0.250 |
Why?
| | Decontamination | 1 | 2006 | 30 | 0.250 |
Why?
| | Amiodarone | 1 | 2005 | 26 | 0.250 |
Why?
| | Anticoagulants | 1 | 2010 | 663 | 0.240 |
Why?
| | Self Report | 4 | 2021 | 822 | 0.240 |
Why?
| | Intention | 1 | 2007 | 169 | 0.240 |
Why?
| | Epilepsy | 2 | 2020 | 331 | 0.240 |
Why?
| | Age Factors | 7 | 2017 | 3284 | 0.240 |
Why?
| | Vasospasm, Intracranial | 1 | 2005 | 17 | 0.240 |
Why?
| | Venous Thrombosis | 1 | 2007 | 190 | 0.240 |
Why?
| | Eating | 4 | 2017 | 379 | 0.240 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2012 | 1462 | 0.240 |
Why?
| | Sodium Nitrite | 1 | 2005 | 39 | 0.230 |
Why?
| | Drug Utilization | 5 | 2014 | 169 | 0.230 |
Why?
| | Calcium | 3 | 2016 | 1197 | 0.230 |
Why?
| | Databases, Factual | 1 | 2010 | 1351 | 0.230 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2005 | 66 | 0.230 |
Why?
| | Education, Medical | 2 | 2021 | 260 | 0.230 |
Why?
| | Diagnostic Imaging | 1 | 2007 | 328 | 0.230 |
Why?
| | Acute Kidney Injury | 1 | 2012 | 809 | 0.230 |
Why?
| | Coma | 2 | 2006 | 32 | 0.230 |
Why?
| | Biomarkers | 7 | 2021 | 4143 | 0.220 |
Why?
| | Hospitals, Urban | 5 | 2021 | 133 | 0.210 |
Why?
| | Triage | 2 | 2025 | 221 | 0.210 |
Why?
| | Injections, Intraperitoneal | 4 | 2009 | 114 | 0.210 |
Why?
| | Hypoglycemic Agents | 2 | 2010 | 1283 | 0.210 |
Why?
| | Anti-Anxiety Agents | 2 | 2020 | 46 | 0.210 |
Why?
| | Animal Experimentation | 1 | 2003 | 6 | 0.210 |
Why?
| | Case-Control Studies | 4 | 2022 | 3540 | 0.210 |
Why?
| | Insulin | 3 | 2019 | 2406 | 0.210 |
Why?
| | Glasgow Coma Scale | 1 | 2004 | 184 | 0.210 |
Why?
| | Calcium Chloride | 1 | 2003 | 12 | 0.200 |
Why?
| | Sensitivity and Specificity | 5 | 2010 | 1935 | 0.200 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 270 | 0.200 |
Why?
| | Hospitals, Teaching | 3 | 2014 | 117 | 0.200 |
Why?
| | Magnesium Sulfate | 1 | 2003 | 17 | 0.200 |
Why?
| | Documentation | 1 | 2024 | 191 | 0.190 |
Why?
| | Cardiopulmonary Resuscitation | 3 | 2018 | 249 | 0.190 |
Why?
| | Placebos | 2 | 2014 | 199 | 0.190 |
Why?
| | Umbilical Cord | 2 | 2021 | 85 | 0.190 |
Why?
| | Longevity | 3 | 2009 | 164 | 0.190 |
Why?
| | Desipramine | 1 | 2001 | 9 | 0.190 |
Why?
| | Phenylurea Compounds | 1 | 2022 | 96 | 0.190 |
Why?
| | Logistic Models | 3 | 2017 | 2067 | 0.190 |
Why?
| | Confidence Intervals | 4 | 2010 | 328 | 0.180 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2023 | 178 | 0.180 |
Why?
| | Fractures, Bone | 2 | 2017 | 376 | 0.180 |
Why?
| | Severity of Illness Index | 1 | 2009 | 2822 | 0.180 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 2021 | 21 | 0.180 |
Why?
| | Narcotic Antagonists | 2 | 2020 | 179 | 0.180 |
Why?
| | Opiate Substitution Treatment | 2 | 2020 | 151 | 0.180 |
Why?
| | Hyperthermia, Induced | 1 | 2022 | 116 | 0.180 |
Why?
| | Research Design | 3 | 2006 | 1127 | 0.180 |
Why?
| | Heart Atria | 1 | 2001 | 137 | 0.170 |
Why?
| | Acute Disease | 2 | 2019 | 1004 | 0.170 |
Why?
| | Myocardial Contraction | 1 | 2001 | 339 | 0.160 |
Why?
| | Immunoglobulin Fragments | 1 | 1999 | 12 | 0.160 |
Why?
| | Lysergic Acid Diethylamide | 1 | 1999 | 2 | 0.160 |
Why?
| | Droperidol | 1 | 1999 | 4 | 0.160 |
Why?
| | Wisconsin | 1 | 2020 | 100 | 0.160 |
Why?
| | Lithium Carbonate | 1 | 1999 | 5 | 0.160 |
Why?
| | Serotonin Syndrome | 1 | 1999 | 4 | 0.160 |
Why?
| | Serotonin Receptor Agonists | 1 | 1999 | 26 | 0.160 |
Why?
| | Survival Analysis | 4 | 2010 | 1321 | 0.160 |
Why?
| | Starch | 1 | 2019 | 22 | 0.160 |
Why?
| | Scorpion Stings | 1 | 1999 | 1 | 0.160 |
Why?
| | Nutritive Value | 1 | 2019 | 37 | 0.160 |
Why?
| | Healthy Volunteers | 2 | 2019 | 199 | 0.160 |
Why?
| | Ventricular Premature Complexes | 1 | 1999 | 36 | 0.160 |
Why?
| | Thrombocytopenia | 1 | 2021 | 198 | 0.160 |
Why?
| | Geriatric Assessment | 2 | 2011 | 224 | 0.160 |
Why?
| | Administration, Oral | 4 | 2019 | 813 | 0.160 |
Why?
| | Community Health Workers | 1 | 2020 | 62 | 0.160 |
Why?
| | Snake Bites | 1 | 1999 | 29 | 0.160 |
Why?
| | Immune System | 1 | 2020 | 177 | 0.150 |
Why?
| | Fallopian Tube Diseases | 1 | 1998 | 4 | 0.150 |
Why?
| | Pregnancy, Tubal | 1 | 1998 | 5 | 0.150 |
Why?
| | Metabolome | 1 | 2022 | 350 | 0.150 |
Why?
| | Munchausen Syndrome by Proxy | 1 | 1998 | 2 | 0.150 |
Why?
| | Abortifacient Agents, Nonsteroidal | 1 | 1998 | 21 | 0.150 |
Why?
| | Dietary Carbohydrates | 1 | 2019 | 155 | 0.150 |
Why?
| | Mass Screening | 1 | 2007 | 1267 | 0.150 |
Why?
| | Drug Therapy, Combination | 4 | 2011 | 1062 | 0.150 |
Why?
| | Plant Extracts | 1 | 2020 | 202 | 0.150 |
Why?
| | Cohort Studies | 7 | 2023 | 5701 | 0.150 |
Why?
| | Chi-Square Distribution | 2 | 2017 | 530 | 0.150 |
Why?
| | Cannabidiol | 1 | 2020 | 119 | 0.140 |
Why?
| | Anticonvulsants | 1 | 2020 | 215 | 0.140 |
Why?
| | Sex Factors | 5 | 2022 | 2060 | 0.140 |
Why?
| | Sulfasalazine | 1 | 1998 | 23 | 0.140 |
Why?
| | Drug Antagonism | 2 | 2009 | 10 | 0.140 |
Why?
| | Out-of-Hospital Cardiac Arrest | 1 | 2018 | 72 | 0.140 |
Why?
| | Faculty, Medical | 1 | 2021 | 283 | 0.140 |
Why?
| | Dietary Fats | 1 | 2019 | 304 | 0.140 |
Why?
| | Drug Interactions | 4 | 2014 | 407 | 0.140 |
Why?
| | Genome-Wide Association Study | 2 | 2023 | 1428 | 0.140 |
Why?
| | Dyspnea | 1 | 1999 | 254 | 0.140 |
Why?
| | Gastrointestinal Agents | 1 | 1998 | 65 | 0.140 |
Why?
| | Methotrexate | 1 | 1998 | 260 | 0.140 |
Why?
| | Continuity of Patient Care | 1 | 2020 | 281 | 0.140 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 303 | 0.130 |
Why?
| | Peptide Fragments | 1 | 2021 | 703 | 0.130 |
Why?
| | Survival Rate | 3 | 2013 | 1962 | 0.130 |
Why?
| | Incidence | 4 | 2013 | 2792 | 0.130 |
Why?
| | Mice | 8 | 2009 | 17733 | 0.130 |
Why?
| | Simulation Training | 1 | 2018 | 99 | 0.130 |
Why?
| | Ammonium Compounds | 1 | 2016 | 3 | 0.130 |
Why?
| | Energy Intake | 1 | 2019 | 484 | 0.130 |
Why?
| | Pain Management | 2 | 2017 | 347 | 0.130 |
Why?
| | Cytochrome P-450 CYP2E1 Inhibitors | 1 | 2016 | 2 | 0.130 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 1044 | 0.130 |
Why?
| | Metabolic Clearance Rate | 2 | 2019 | 115 | 0.130 |
Why?
| | Prenatal Care | 1 | 2019 | 288 | 0.130 |
Why?
| | Hypnotics and Sedatives | 1 | 1998 | 198 | 0.130 |
Why?
| | Half-Life | 2 | 2019 | 164 | 0.130 |
Why?
| | Ventricular Fibrillation | 1 | 2016 | 60 | 0.130 |
Why?
| | Pharmacovigilance | 1 | 2015 | 23 | 0.120 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 2022 | 0.120 |
Why?
| | Milk | 1 | 2016 | 124 | 0.120 |
Why?
| | Herniorrhaphy | 1 | 2016 | 60 | 0.120 |
Why?
| | Genetic Variation | 1 | 2020 | 985 | 0.120 |
Why?
| | Fatal Outcome | 2 | 2013 | 303 | 0.120 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2015 | 77 | 0.120 |
Why?
| | Pilot Projects | 1 | 2020 | 1692 | 0.120 |
Why?
| | Hemodialysis Units, Hospital | 1 | 1994 | 5 | 0.110 |
Why?
| | Models, Biological | 2 | 2015 | 1773 | 0.110 |
Why?
| | Child Behavior | 1 | 2017 | 246 | 0.110 |
Why?
| | Ondansetron | 1 | 2014 | 16 | 0.110 |
Why?
| | Liver Failure, Acute | 1 | 2015 | 65 | 0.110 |
Why?
| | Patient Simulation | 1 | 2014 | 35 | 0.110 |
Why?
| | Total Quality Management | 1 | 1994 | 61 | 0.110 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2014 | 30 | 0.110 |
Why?
| | Hydrocodone | 1 | 2014 | 17 | 0.110 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2015 | 94 | 0.110 |
Why?
| | Transaminases | 1 | 2014 | 24 | 0.110 |
Why?
| | Oxycodone | 1 | 2014 | 42 | 0.110 |
Why?
| | Curriculum | 1 | 2021 | 976 | 0.110 |
Why?
| | Internship and Residency | 2 | 2014 | 1132 | 0.110 |
Why?
| | Guanfacine | 1 | 2013 | 4 | 0.110 |
Why?
| | Remote Consultation | 1 | 2014 | 50 | 0.110 |
Why?
| | Physicians | 2 | 2020 | 907 | 0.110 |
Why?
| | Clonidine | 1 | 2013 | 28 | 0.110 |
Why?
| | International Normalized Ratio | 2 | 2011 | 47 | 0.110 |
Why?
| | Pregnancy Complications | 1 | 2019 | 524 | 0.110 |
Why?
| | Prognosis | 3 | 2011 | 4013 | 0.110 |
Why?
| | Acute Pain | 1 | 2014 | 49 | 0.100 |
Why?
| | Cesium | 1 | 2013 | 20 | 0.100 |
Why?
| | Vitamins | 1 | 2015 | 185 | 0.100 |
Why?
| | Food | 1 | 2015 | 160 | 0.100 |
Why?
| | Indazoles | 1 | 2014 | 69 | 0.100 |
Why?
| | Deoxycholic Acid | 1 | 2013 | 14 | 0.100 |
Why?
| | Lethargy | 1 | 2012 | 4 | 0.100 |
Why?
| | Pain Measurement | 4 | 2019 | 521 | 0.100 |
Why?
| | Duloxetine Hydrochloride | 1 | 2012 | 11 | 0.100 |
Why?
| | Walking | 1 | 2017 | 523 | 0.100 |
Why?
| | Dabigatran | 1 | 2012 | 22 | 0.100 |
Why?
| | Canada | 2 | 2025 | 417 | 0.100 |
Why?
| | Sleep Stages | 1 | 2012 | 47 | 0.100 |
Why?
| | Tachycardia | 1 | 2012 | 57 | 0.100 |
Why?
| | Chlorides | 1 | 2013 | 136 | 0.100 |
Why?
| | Pyrazoles | 1 | 2016 | 423 | 0.100 |
Why?
| | Sulfhydryl Reagents | 1 | 2012 | 12 | 0.100 |
Why?
| | Attitude of Health Personnel | 1 | 2020 | 1163 | 0.100 |
Why?
| | Mycoses | 1 | 2013 | 79 | 0.100 |
Why?
| | Marijuana Abuse | 1 | 2015 | 232 | 0.100 |
Why?
| | Dizziness | 1 | 2012 | 82 | 0.090 |
Why?
| | Data Collection | 2 | 2013 | 668 | 0.090 |
Why?
| | Sampling Studies | 1 | 2012 | 99 | 0.090 |
Why?
| | Arsenicals | 1 | 2012 | 30 | 0.090 |
Why?
| | Athletic Performance | 1 | 2013 | 79 | 0.090 |
Why?
| | Magnesium | 2 | 2004 | 156 | 0.090 |
Why?
| | Patient Discharge | 2 | 2016 | 894 | 0.090 |
Why?
| | Drug Combinations | 1 | 2013 | 343 | 0.090 |
Why?
| | Accidental Falls | 2 | 2011 | 193 | 0.090 |
Why?
| | Information Systems | 1 | 2011 | 61 | 0.090 |
Why?
| | Sulfides | 1 | 2012 | 99 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 249 | 0.090 |
Why?
| | Follow-Up Studies | 3 | 2010 | 5106 | 0.090 |
Why?
| | Arabia | 1 | 2011 | 2 | 0.090 |
Why?
| | Levamisole | 1 | 2011 | 19 | 0.090 |
Why?
| | Laparoscopy | 1 | 2016 | 464 | 0.090 |
Why?
| | Immunocompromised Host | 1 | 2013 | 202 | 0.090 |
Why?
| | Hepatic Encephalopathy | 1 | 2011 | 21 | 0.090 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 570 | 0.090 |
Why?
| | Drug Contamination | 1 | 2011 | 53 | 0.090 |
Why?
| | Molecular Structure | 1 | 2012 | 489 | 0.090 |
Why?
| | Dietary Supplements | 1 | 2015 | 559 | 0.080 |
Why?
| | Pharmacogenetics | 1 | 2012 | 179 | 0.080 |
Why?
| | Universities | 1 | 2013 | 433 | 0.080 |
Why?
| | Glipizide | 1 | 2010 | 6 | 0.080 |
Why?
| | Laboratories, Hospital | 1 | 2010 | 15 | 0.080 |
Why?
| | Hepatitis, Alcoholic | 1 | 2010 | 13 | 0.080 |
Why?
| | Sports | 1 | 2013 | 231 | 0.080 |
Why?
| | Troponin | 1 | 2010 | 50 | 0.080 |
Why?
| | Glyburide | 1 | 2010 | 32 | 0.080 |
Why?
| | Drug Prescriptions | 2 | 2016 | 243 | 0.080 |
Why?
| | Crowding | 1 | 2010 | 35 | 0.080 |
Why?
| | Biological Availability | 2 | 2019 | 148 | 0.080 |
Why?
| | Watchful Waiting | 1 | 2010 | 80 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2011 | 226 | 0.080 |
Why?
| | Body Weight | 1 | 2014 | 985 | 0.080 |
Why?
| | Quetiapine Fumarate | 1 | 2009 | 23 | 0.080 |
Why?
| | Dibenzothiazepines | 1 | 2009 | 17 | 0.080 |
Why?
| | Aripiprazole | 1 | 2009 | 20 | 0.080 |
Why?
| | Risperidone | 1 | 2009 | 29 | 0.080 |
Why?
| | Potassium | 1 | 2009 | 147 | 0.080 |
Why?
| | Role | 1 | 2009 | 31 | 0.080 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 139 | 0.080 |
Why?
| | Head Protective Devices | 1 | 2009 | 24 | 0.080 |
Why?
| | Dogs | 1 | 2010 | 411 | 0.080 |
Why?
| | Quality Control | 1 | 2009 | 171 | 0.080 |
Why?
| | Renal Dialysis | 1 | 2013 | 435 | 0.080 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2011 | 233 | 0.080 |
Why?
| | Glutathione | 3 | 2022 | 356 | 0.070 |
Why?
| | Acidosis | 2 | 2006 | 101 | 0.070 |
Why?
| | Bibliometrics | 1 | 2009 | 63 | 0.070 |
Why?
| | Verapamil | 2 | 2014 | 41 | 0.070 |
Why?
| | Body Temperature | 1 | 2009 | 221 | 0.070 |
Why?
| | Diarrhea | 1 | 2009 | 184 | 0.070 |
Why?
| | Workload | 1 | 2010 | 160 | 0.070 |
Why?
| | Quality Indicators, Health Care | 1 | 2011 | 307 | 0.070 |
Why?
| | Skiing | 1 | 2009 | 45 | 0.070 |
Why?
| | Informed Consent | 2 | 2006 | 172 | 0.070 |
Why?
| | Bacitracin | 1 | 2008 | 6 | 0.070 |
Why?
| | Adhesiveness | 1 | 2008 | 20 | 0.070 |
Why?
| | Pharmacy Service, Hospital | 1 | 2009 | 90 | 0.070 |
Why?
| | Acetone | 1 | 2008 | 11 | 0.070 |
Why?
| | Hair Preparations | 1 | 2008 | 8 | 0.070 |
Why?
| | Nylons | 1 | 2008 | 18 | 0.070 |
Why?
| | Health Services Accessibility | 1 | 2015 | 978 | 0.070 |
Why?
| | Propylene Glycols | 1 | 2008 | 28 | 0.070 |
Why?
| | Cellulose | 1 | 2008 | 39 | 0.070 |
Why?
| | Equipment Design | 1 | 2009 | 521 | 0.070 |
Why?
| | Cause of Death | 1 | 2010 | 430 | 0.070 |
Why?
| | Withholding Treatment | 1 | 2008 | 76 | 0.070 |
Why?
| | Military Personnel | 1 | 2014 | 544 | 0.070 |
Why?
| | Students | 1 | 2013 | 622 | 0.070 |
Why?
| | Glycerol | 1 | 2008 | 94 | 0.070 |
Why?
| | Quinolones | 1 | 2009 | 137 | 0.070 |
Why?
| | Drug Synergism | 1 | 2008 | 382 | 0.070 |
Why?
| | Nephelometry and Turbidimetry | 1 | 2007 | 13 | 0.070 |
Why?
| | Substance Abuse Detection | 2 | 2021 | 87 | 0.070 |
Why?
| | Laboratories | 1 | 2008 | 112 | 0.070 |
Why?
| | Polypharmacy | 1 | 2008 | 85 | 0.070 |
Why?
| | Tissue Distribution | 2 | 2019 | 330 | 0.070 |
Why?
| | Phosphates | 1 | 2008 | 182 | 0.070 |
Why?
| | Formates | 1 | 2006 | 13 | 0.070 |
Why?
| | Research | 2 | 2011 | 448 | 0.070 |
Why?
| | Defibrillators | 1 | 2006 | 16 | 0.060 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1231 | 0.060 |
Why?
| | Methanol | 1 | 2006 | 38 | 0.060 |
Why?
| | Periodicals as Topic | 1 | 2009 | 208 | 0.060 |
Why?
| | Blindness | 1 | 2006 | 38 | 0.060 |
Why?
| | Vasopressins | 1 | 2006 | 64 | 0.060 |
Why?
| | Statistics, Nonparametric | 1 | 2007 | 431 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 2013 | 701 | 0.060 |
Why?
| | Probability | 2 | 2010 | 304 | 0.060 |
Why?
| | Respiratory Insufficiency | 1 | 2009 | 317 | 0.060 |
Why?
| | Hospitalization | 2 | 2011 | 2183 | 0.060 |
Why?
| | Spinal Diseases | 1 | 2006 | 48 | 0.060 |
Why?
| | Naproxen | 1 | 2006 | 17 | 0.060 |
Why?
| | Epinephrine | 1 | 2006 | 139 | 0.060 |
Why?
| | Ipecac | 1 | 2005 | 8 | 0.060 |
Why?
| | Health Services for the Aged | 1 | 2006 | 80 | 0.060 |
Why?
| | Aging | 2 | 2014 | 1861 | 0.060 |
Why?
| | Population Dynamics | 1 | 2006 | 149 | 0.060 |
Why?
| | Hospitals, University | 1 | 2006 | 182 | 0.060 |
Why?
| | Ibuprofen | 1 | 2006 | 84 | 0.060 |
Why?
| | Haplorhini | 1 | 2005 | 52 | 0.060 |
Why?
| | Telemedicine | 1 | 2014 | 851 | 0.060 |
Why?
| | Premedication | 1 | 2005 | 44 | 0.060 |
Why?
| | Respiration, Artificial | 1 | 2009 | 642 | 0.060 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1571 | 0.060 |
Why?
| | Geriatrics | 1 | 2006 | 98 | 0.060 |
Why?
| | Risk | 1 | 2007 | 908 | 0.060 |
Why?
| | Spine | 1 | 2006 | 173 | 0.060 |
Why?
| | Single-Blind Method | 1 | 2005 | 282 | 0.060 |
Why?
| | Water | 1 | 2008 | 457 | 0.060 |
Why?
| | Fluoride Poisoning | 1 | 2004 | 3 | 0.050 |
Why?
| | Phenobarbital | 1 | 2023 | 19 | 0.050 |
Why?
| | Motivation | 1 | 2009 | 567 | 0.050 |
Why?
| | Resuscitation | 1 | 2006 | 250 | 0.050 |
Why?
| | Blood Glucose | 2 | 2019 | 2181 | 0.050 |
Why?
| | Hydroxyzine | 1 | 2023 | 4 | 0.050 |
Why?
| | Maltose | 1 | 2023 | 7 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2005 | 275 | 0.050 |
Why?
| | Delphi Technique | 1 | 2025 | 273 | 0.050 |
Why?
| | Health Policy | 1 | 2006 | 385 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2004 | 117 | 0.050 |
Why?
| | Sheep | 1 | 2006 | 856 | 0.050 |
Why?
| | Urea | 1 | 2023 | 81 | 0.050 |
Why?
| | Survival | 1 | 2003 | 38 | 0.050 |
Why?
| | Patient Participation | 1 | 2006 | 418 | 0.050 |
Why?
| | Aspirin | 1 | 2006 | 387 | 0.050 |
Why?
| | Pregnancy | 3 | 2021 | 6728 | 0.050 |
Why?
| | Internet | 1 | 2007 | 647 | 0.050 |
Why?
| | Lactates | 1 | 2022 | 85 | 0.050 |
Why?
| | Sex Distribution | 2 | 2015 | 373 | 0.050 |
Why?
| | Culture Techniques | 1 | 2001 | 81 | 0.050 |
Why?
| | Urban Population | 2 | 2019 | 476 | 0.050 |
Why?
| | Prevalence | 3 | 2015 | 2711 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 678 | 0.050 |
Why?
| | Blood Physiological Phenomena | 1 | 2021 | 13 | 0.050 |
Why?
| | Neural Conduction | 1 | 2001 | 86 | 0.050 |
Why?
| | Academic Medical Centers | 2 | 2016 | 504 | 0.040 |
Why?
| | Hirudins | 1 | 2021 | 53 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2234 | 0.040 |
Why?
| | Calcium Channel Blockers | 1 | 2001 | 167 | 0.040 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2020 | 30 | 0.040 |
Why?
| | Infusions, Parenteral | 1 | 2020 | 40 | 0.040 |
Why?
| | Pirenzepine | 1 | 1999 | 7 | 0.040 |
Why?
| | Scorpions | 1 | 1999 | 3 | 0.040 |
Why?
| | Certification | 1 | 2020 | 103 | 0.040 |
Why?
| | South America | 1 | 1999 | 59 | 0.040 |
Why?
| | Blood Cell Count | 2 | 2013 | 55 | 0.040 |
Why?
| | Narcotics | 1 | 1999 | 52 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 539 | 0.040 |
Why?
| | Temperature | 1 | 2022 | 675 | 0.040 |
Why?
| | Rupture, Spontaneous | 1 | 1998 | 17 | 0.040 |
Why?
| | Postprandial Period | 1 | 2019 | 107 | 0.040 |
Why?
| | Central Nervous System Depressants | 1 | 1999 | 85 | 0.040 |
Why?
| | Manikins | 1 | 2018 | 28 | 0.040 |
Why?
| | Videotape Recording | 1 | 2018 | 35 | 0.040 |
Why?
| | Sorption Detoxification | 1 | 1998 | 2 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2001 | 1316 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2004 | 889 | 0.040 |
Why?
| | Cholinesterase Inhibitors | 1 | 1998 | 30 | 0.040 |
Why?
| | North America | 1 | 1999 | 312 | 0.040 |
Why?
| | Dietary Proteins | 1 | 2019 | 135 | 0.040 |
Why?
| | Laparotomy | 1 | 1998 | 109 | 0.040 |
Why?
| | Feedback | 1 | 2018 | 173 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2021 | 1350 | 0.040 |
Why?
| | Lipids | 1 | 2022 | 665 | 0.030 |
Why?
| | Cardiomyopathies | 1 | 2001 | 348 | 0.030 |
Why?
| | Central Nervous System | 1 | 1999 | 258 | 0.030 |
Why?
| | Maternal Health Services | 1 | 2019 | 97 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2019 | 562 | 0.030 |
Why?
| | Triglycerides | 1 | 2019 | 524 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2001 | 887 | 0.030 |
Why?
| | Registries | 2 | 2010 | 2015 | 0.030 |
Why?
| | Socioeconomic Factors | 2 | 2015 | 1282 | 0.030 |
Why?
| | Bipolar Disorder | 1 | 1999 | 263 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 1059 | 0.030 |
Why?
| | Hallucinogens | 1 | 2017 | 104 | 0.030 |
Why?
| | Dialysis | 1 | 2015 | 20 | 0.030 |
Why?
| | Centrifugation | 1 | 2015 | 30 | 0.030 |
Why?
| | Tennessee | 1 | 1994 | 44 | 0.030 |
Why?
| | Observation | 1 | 2014 | 50 | 0.030 |
Why?
| | Hematocrit | 1 | 1994 | 96 | 0.030 |
Why?
| | Anesthetics, Local | 1 | 2014 | 80 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 889 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2015 | 132 | 0.030 |
Why?
| | Syndrome | 1 | 2015 | 357 | 0.030 |
Why?
| | Warfare | 1 | 2014 | 68 | 0.030 |
Why?
| | Injections, Intralesional | 1 | 2013 | 34 | 0.030 |
Why?
| | Erythropoietin | 1 | 1994 | 95 | 0.030 |
Why?
| | Protein Binding | 1 | 2020 | 2216 | 0.030 |
Why?
| | Hospitals, Veterans | 1 | 1994 | 249 | 0.030 |
Why?
| | Salicylates | 1 | 2013 | 28 | 0.030 |
Why?
| | Urinalysis | 1 | 2013 | 77 | 0.020 |
Why?
| | Nursing Staff, Hospital | 1 | 1994 | 153 | 0.020 |
Why?
| | Long QT Syndrome | 1 | 2013 | 70 | 0.020 |
Why?
| | Hemoglobins | 1 | 1994 | 353 | 0.020 |
Why?
| | Iron | 1 | 1994 | 312 | 0.020 |
Why?
| | Therapeutic Irrigation | 1 | 2012 | 77 | 0.020 |
Why?
| | Receptors, Opioid, mu | 1 | 2012 | 74 | 0.020 |
Why?
| | Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2011 | 7 | 0.020 |
Why?
| | Agranulocytosis | 1 | 2011 | 30 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2011 | 53 | 0.020 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2012 | 155 | 0.020 |
Why?
| | Leukoencephalopathies | 1 | 2011 | 19 | 0.020 |
Why?
| | Computer Simulation | 1 | 2015 | 973 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2019 | 1203 | 0.020 |
Why?
| | Toothache | 1 | 2010 | 5 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2011 | 132 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2012 | 147 | 0.020 |
Why?
| | Models, Theoretical | 1 | 1994 | 575 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2015 | 634 | 0.020 |
Why?
| | Immunoassay | 1 | 2011 | 113 | 0.020 |
Why?
| | Drug Administration Routes | 1 | 2010 | 38 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2014 | 387 | 0.020 |
Why?
| | Insurance Coverage | 1 | 2012 | 229 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2010 | 206 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2010 | 110 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 1994 | 761 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 389 | 0.020 |
Why?
| | Intestines | 1 | 2012 | 357 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 659 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 1994 | 566 | 0.020 |
Why?
| | Safety | 1 | 2010 | 338 | 0.020 |
Why?
| | Precision Medicine | 1 | 2012 | 426 | 0.020 |
Why?
| | Ethanol | 1 | 2012 | 606 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 1022 | 0.020 |
Why?
| | Seasons | 1 | 2010 | 544 | 0.020 |
Why?
| | Clinical Competence | 1 | 2014 | 1094 | 0.020 |
Why?
| | Bilirubin | 1 | 2007 | 97 | 0.020 |
Why?
| | Disease Management | 1 | 2011 | 624 | 0.020 |
Why?
| | Pulse | 1 | 2006 | 23 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 1914 | 0.020 |
Why?
| | Blastomycosis | 1 | 2006 | 10 | 0.020 |
Why?
| | Metabolomics | 1 | 2012 | 678 | 0.020 |
Why?
| | Contraindications | 1 | 2006 | 90 | 0.020 |
Why?
| | Amyloidosis | 1 | 2006 | 42 | 0.020 |
Why?
| | Coronary Circulation | 1 | 2006 | 140 | 0.020 |
Why?
| | Biopsy, Fine-Needle | 1 | 2006 | 68 | 0.020 |
Why?
| | Electric Countershock | 1 | 2006 | 107 | 0.020 |
Why?
| | European Union | 1 | 2005 | 12 | 0.020 |
Why?
| | Fever | 1 | 2007 | 306 | 0.020 |
Why?
| | Disaster Planning | 1 | 2006 | 89 | 0.010 |
Why?
| | Emergencies | 1 | 2006 | 164 | 0.010 |
Why?
| | Infant, Newborn | 2 | 2007 | 6033 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 2006 | 683 | 0.010 |
Why?
| | United States Food and Drug Administration | 1 | 2005 | 208 | 0.010 |
Why?
| | Up-Regulation | 1 | 2007 | 843 | 0.010 |
Why?
| | Renal Insufficiency | 1 | 2006 | 155 | 0.010 |
Why?
| | Pharmaceutical Preparations | 1 | 2006 | 179 | 0.010 |
Why?
| | Swine | 1 | 2006 | 773 | 0.010 |
Why?
| | Mice, Inbred ICR | 1 | 2004 | 119 | 0.010 |
Why?
| | Brain Injuries | 1 | 2009 | 494 | 0.010 |
Why?
| | Lupus Nephritis | 1 | 2004 | 63 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3188 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2004 | 1089 | 0.010 |
Why?
| | Papillary Muscles | 1 | 2001 | 13 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2001 | 195 | 0.010 |
Why?
| | Miosis | 1 | 1999 | 3 | 0.010 |
Why?
| | Pupil | 1 | 1999 | 15 | 0.010 |
Why?
| | Blood Pressure | 1 | 2006 | 1774 | 0.010 |
Why?
| | Hemodynamics | 1 | 2004 | 1110 | 0.010 |
Why?
| | Chronic Disease | 1 | 2004 | 1784 | 0.010 |
Why?
| | Algorithms | 1 | 2004 | 1689 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2001 | 2486 | 0.010 |
Why?
| | Rats | 1 | 2001 | 5639 | 0.010 |
Why?
| | Neoplasms | 1 | 2006 | 2644 | 0.010 |
Why?
|
|
Heard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|